My SciELO
Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Actas Urológicas Españolas
Print version ISSN 0210-4806
Abstract
JALON MONZON, A. et al. Therapeutic effect of Mitomycin C in the immediate postoperatory in patients with low-risk non-muscle-invasive bladder tumours. Actas Urol Esp [online]. 2008, vol.32, n.8, pp.811-820. ISSN 0210-4806.
Introduction: Bladder cancer is a disease with a high prevalence due to its recurrence rate. Transurethral resection of the bladder (TURB) is the treatment in initial stages. Nevertheless, a high percentage of non-muscle-invasive tumors treated will have a recurrence 1-2 years afterwards. Adjuvant quemotherapy or immunotherapy after TURB has been administered in order to decrease the rate of recurrence and to prevent progression. Patients and methods: A prospectived, controlled and randomized study was performed. We included 100 patients with non-muscle-invasive and bladder tumors the low grade. All patients had initially a TURB performed and were randomized to either receive or not a single dose mitomycin C (MMC) in the immediate postoperatory. Results: All low grade tumors was less than 3 cm. Mean follow-up was 26,43±7,65 months. MMC was administered in 49 patients, of these, 67,3% had no recurrence and 32,7% had a non-muscle-invasive recurrence. Of the 51 patients in the non mitomycin, 51% had no recurrence while 47% had a non-muscle-invasive recurrence, and 2% had a muscle-invasive progression. We found significantly differences in time to recurrence among the two groups. Summary: We found a greater time to recurrence in the group of single dose adjuvant MMC being this difference statistically significantly when comparing with the other group.
Keywords : Non muscle-invasive; Bladder cancer; Intravesical therapy; Chemotherapy; Mitomycin C.